Navigation Links
Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
Date:9/14/2007

Long-Term Outlook More Favorable as Drugs from Eli Lilly and GlaxoSmithKline Will Drive the Market in 2016, According to a New Report

from Decision Resources

WALTHAM, Mass., Sept. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of Merck's Proscar and Boehringer Ingelheim/Astellas's Flomax/Harnal, combined with the limited emergence of new therapies, will cause a 23% decline in sales of therapies to treat benign prostatic hyperplasia over the next five years.

The new Pharmacor report entitled Benign Prostatic Hyperplasia finds that the market to treat the disease is dominated by two drug classes-alpha blockers and 5-alpha-reductase inhibitors-which make up 93% of drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The report finds that the patent expiries of Proscar and Flomax/Harnal will cause a significant decline in the overall benign prostatic hyperplasia market by 2011.

Although patent expiries will constrain the market in the near term, increases in the patient population, unmet need, and higher drug treatment rates from 2011 to 2016 will help create a favorable landscape for novel benign prostatic hyperplasia treatments.

"Eli Lilly's Cialis and GlaxoSmithKline's fixed-dose combination of tamsulosin and dutasteride, both of which are expected to launch for benign prostatic hyperplasia in the United States and in Europe by 2011, are the two most promising agents in the pipeline," said Greg Dwyer, analyst at Decision Resources. "The combined sales of these two drugs will represent nearly 30% of the total benign prostatic hyperplasia market in 2016."

To listen to an interview with Mr. Dwyer regarding the benign prostatic hyperplasia drug market, please visit the Find Out More section of the Decision Resources home page on September 17, 2007, at http://www.DecisionResources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian Doctor granted US patent on organ regeneration
2. Dr Reddy’s Laboratories to challenge patents on drug
3. Yoga, ayurveda being documented to stop patent misuse
4. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
5. US Court Rules Against Lupin in Ramipril Patent Case
6. HIV Patients Opposes Patenting Of AIDS Drug
7. Provigil Patent Extension Accorded To Cephalon
8. AIDS Sufferers Protest against Proposed Patent for Tenofovir
9. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
10. Venus Remedies Files 5th International Patent Application
11. Patent for Seminal RNAi innovation Cleared in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, 2016 , ... ... operation with him running plumbing calls throughout the beach community. His vision to grow ... at affordable rates and ensuring they maintain the highest level of training and customer ...
(Date:5/26/2016)... ... May 26, 2016 , ... According to the Webster’s dictionary, a ... with chemical-laden beauty products, one company is going against the norm with a line ... The rising star in the green space is proud to announce its latest retail ...
(Date:5/26/2016)... ... May 26, 2016 , ... HealthPostures, ergonomics designer and ... , furniture that may support women during pregnancy. Potential benefits of using the Stance ... rest and comfort and healthier levels of sitting and standing. , Need for the ...
(Date:5/25/2016)... Miami, Florida (PRWEB) , ... May 26, 2016 , ... ... for the treatment of androgenetic alopecia in both men and women. To date, the ... laser caps with FDA clearance for any adult who suffers with androgenetic alopecia. ...
(Date:5/25/2016)... Chicago, IL (PRWEB) , ... May 25, 2016 ... ... HealthScape Advisors,” said Steven Young, a Managing Partner at HealthScape Advisors. “Brad brings ... value-based care within the healthcare delivery system accelerates with the implementation of MACRA, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual therapy ... intervention   OrbusNeich, a global company specializing ... its portfolio to include products to treat peripheral artery ... company,s first entry devices for lower limb and arteriovenous ...
(Date:5/24/2016)... -- Open Access Journal Focusing on ... Elsevier , a world-leading provider of scientific, technical ... launch of Clinical Neurophysiology Practice ... clinical practice issues in clinical neurophysiology. The journal will ... and didactic reviews. It is an official journal of ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
Breaking Medicine Technology: